TLIK.F down 31% intraday on XETRA 09 Feb 2026: watch liquidity and valuation

The TLIK.F stock plunged 31.05% intraday on XETRA to €0.262 on 09 Feb 2026, making Arzneiwerk AG VIDA one of today’s top losers. The fall follows thin trading—volume 500 vs average 470—and highlights the firm’s low liquidity and weak balance-sheet metrics. Investors should note the negative earnings trend: EPS €-0.11 and PE -2.38. With the Healthcare sector up modestly today, TLIK.F’s move looks stock-specific and raises short-term downside risk while opening a scenario-based recovery path for traders watching valuation and float activity.

Price action: TLIK.F stock intraday slide

Arzneiwerk AG VIDA (TLIK.F) fell 31.05% to €0.262 on XETRA intraday trading. The session range was narrow with a day low €0.260 and day high €0.262, and the stock opened at €0.260. One-day performance is sharp compared with a 5-day gain of 19.09%, signalling rapid sentiment swings in the micro-cap name.

Drivers and liquidity: TLIK.F stock trading context

No scheduled earnings or company announcement explains the drop; low free float and tiny market cap raise volatility. Market cap stands at EUR 1,633,156.00 with shares outstanding 6,233,420.00, and intraday volume 500.00 only slightly above average 470.00. Thin liquidity amplifies moves and makes large percentage swings more likely for TLIK.F stock.

Fundamentals and ratios: TLIK.F stock financials

Fundamentals remain weak: EPS €-0.11, trailing PE -2.38, cash per share €0.00083, and current ratio 0.04. Operating cash flow per share is €-0.35 and free cash flow per share is €-0.34, showing limited cash generation. These metrics point to continued funding and solvency risk unless revenues and margins improve.

Meyka grade and technical view: TLIK.F stock rating

Meyka AI rates TLIK.F with a score out of 100: 62.77 (B, HOLD). This grade factors in S&P 500 comparison, sector and industry peers, financial growth, key metrics, forecasts, and analyst consensus. Note an independent company rating flagged D+ / Strong Sell on 06 Feb 2026, underscoring divergence between quantitative grading and third-party risk signals.

Valuation and price targets: TLIK.F stock outlook

Meyka AI’s forecast model projects a monthly price near €0.27, implying +3.05% from the current €0.262. Scenario targets: a conservative downside target €0.10 (implied -61.83%) and a recovery target €0.50 (implied +90.84%). These targets are scenario-based and reflect thin trading, not formal analyst coverage. Forecasts are model-based projections and not guarantees.

Risk and sector comparison: TLIK.F stock in Healthcare

The Healthcare sector is modestly positive today while TLIK.F underperformed; sector 1-day change is +1.09% versus TLIK.F -31.05%. Key risks: micro-cap liquidity, negative operating cash flow, and low employee base (2.00). Opportunities depend on product supply wins for rare medicines, but execution and capital are the main hurdles before valuation improves.

Final Thoughts

TLIK.F stock’s intraday 31.05% drop to €0.262 on XETRA on 09 Feb 2026 highlights micro-cap fragility. The immediate drivers appear to be poor liquidity—volume 500.00—and weak fundamentals: EPS €-0.11, PE -2.38, current ratio 0.04, and operating cash flow per share €-0.35. Meyka AI’s quantitative grade scores 62.77/100 (B, HOLD), while an independent D+ rating flagged a strong sell signal, showing mixed signals between model scoring and risk metrics. Meyka AI’s forecast model projects €0.27 monthly, a +3.05% implied move from the current price; scenario targets stretch from €0.10 downside to €0.50 recovery. Given the tiny market cap EUR 1,633,156.00, low float, and tight trading ranges, short-term traders may find volatility-driven opportunities but long-term investors should require clearer revenue or cash flows before adding exposure. This piece uses Meyka AI as an AI-powered market analysis platform and is informational only, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.